Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven A Sahn

Showing results (61-70 of 74) with videos related to

Pageof 8
Sort By:
Chest|February 20, 2009
Clinical profile of anti-PL-12 autoantibody. Cohort study and review of the literatureMeena Kalluri, Steven A Sahn, Chester V Oddis, et al.
American Journal of Respiratory and Critical Care Medicine|January 31, 2014
All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trialsTalmadge E King, Carlo Albera, Williamson Z Bradford, et al.
Respirology (Carlton, Vic.)|August 16, 2014
Characteristics of patients with yellow nail syndrome and pleural effusionLuis Valdés, John T Huggins, Francisco Gude, et al.
Respiratory Medicine|May 10, 2015
Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosisSteven D Nathan, Roland M du Bois, Carlo Albera, et al.
Archivos De Bronconeumologia|April 9, 2011
Diagnostic value of N-terminal pro-brain natriuretic peptide in pleural effusions of cardiac originLuis Valdés, Esther San José, Antonio Pose, et al.
Lancet (London, England)|July 3, 2009
Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trialTalmadge E King, Carlo Albera, Williamson Z Bradford, et al.
Lancet (London, England)|May 17, 2011
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trialsPaul W Noble, Carlo Albera, Williamson Z Bradford, et al.
American Journal of Respiratory and Critical Care Medicine|December 7, 2010
Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important differenceRoland M du Bois, Derek Weycker, Carlo Albera, et al.
American Journal of Respiratory and Critical Care Medicine|September 24, 2011
Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important differenceRoland M du Bois, Derek Weycker, Carlo Albera, et al.
American Journal of Respiratory and Critical Care Medicine|May 28, 2011
Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosisRoland M du Bois, Derek Weycker, Carlo Albera, et al.
Pageof 8

Showing results (61-70 of 74) with videos related to

Sort By:
Pageof 8
Chest|February 20, 2009
Clinical profile of anti-PL-12 autoantibody. Cohort study and review of the literatureMeena Kalluri, Steven A Sahn, Chester V Oddis, et al.
American Journal of Respiratory and Critical Care Medicine|January 31, 2014
All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trialsTalmadge E King, Carlo Albera, Williamson Z Bradford, et al.
Respirology (Carlton, Vic.)|August 16, 2014
Characteristics of patients with yellow nail syndrome and pleural effusionLuis Valdés, John T Huggins, Francisco Gude, et al.
Respiratory Medicine|May 10, 2015
Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosisSteven D Nathan, Roland M du Bois, Carlo Albera, et al.
Archivos De Bronconeumologia|April 9, 2011
Diagnostic value of N-terminal pro-brain natriuretic peptide in pleural effusions of cardiac originLuis Valdés, Esther San José, Antonio Pose, et al.
Lancet (London, England)|July 3, 2009
Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trialTalmadge E King, Carlo Albera, Williamson Z Bradford, et al.
Lancet (London, England)|May 17, 2011
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trialsPaul W Noble, Carlo Albera, Williamson Z Bradford, et al.
American Journal of Respiratory and Critical Care Medicine|December 7, 2010
Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important differenceRoland M du Bois, Derek Weycker, Carlo Albera, et al.
American Journal of Respiratory and Critical Care Medicine|September 24, 2011
Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important differenceRoland M du Bois, Derek Weycker, Carlo Albera, et al.
American Journal of Respiratory and Critical Care Medicine|May 28, 2011
Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosisRoland M du Bois, Derek Weycker, Carlo Albera, et al.
Pageof 8